Abstract
Aims: Infliximab (IFX), an anti-tumor necrosis factor-monoclonal chimeric antibody, has been shown to be an extremely potent drug for acute and maintenance treatment of both adult and pediatric patients with severe IBD, especially in those with Crohn's disease (CD). The aim of this retrospective study was to assess the efficacy and the tolerability profile in pediatric patients affected by CD and ulcerative colitis (UC).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
